CDKN2A and lung adenocarcinoma: In lung adenocarcinoma specimens, no relationship was observed between CDKN2A deletion and immune-inflamed phenotype, unlike PD-L1, suggesting it may be a mechanistically distinct predictor of checkpoint inhibitor efficacy.